GoingToMeet

Driving value in phase IIIb & IV trials - announcing the USA’s first strategic late phase development congress

Following industry demand, we are proud to announce that Late Phase Drug Development World Americas is now open for business. This unique industry led forum follows on from our highly successful European meeting and brings together the top pharmaceutical, biotechnology and CRO representatives in a forum that ensures we tackle the crucial challenges faced by the industry.

Post approval studies are growing at around 20% annually, exceeding the growth rate of phase II and III trials. In excess of $12 billion is currently being spent on phase IIIb/IV studies as public concerns on the safety of approved drugs prevail together with the need to evaluate real world safety and effectiveness of marketed drugs. More than ever before there is the urgent need to detect, quantify and communicate patient risk with speed and efficiency.

For more information visit www.healthnetworkcommunications.com/2010/lpddusa